Table 1.
The most important characteristics of different CS-NPs (selection).
| CS-NPs | NPs Size (nm) |
DLE (%) |
DR (%) |
Mw/DD of CS |
ZP (mV) |
Ref. |
|---|---|---|---|---|---|---|
| Insulin CS-NPs |
534 ± 24 | 80 ± 3.96% | 14%(pH 2) 85–88% (pH 6.8) (after 10 h) |
CS LMw 150 kDa DD 95% |
14.57 ± 1.1 | [27] |
| Docetaxel solid-lipid CS-NPs | 235 ± 4.2 | 94 ± 3.1% | 84 ± 3.1% (donor: acceptor lipid-1:25) 88 ± 2.5% (donor: acceptor lipid-1:100) |
CS HMw 310 kDa DD 75% |
29.0 ± 3.5 | [31] |
| Sodium ceftriaxone CS-NPs |
265 ± 3.5 | 79 ± 0.9% | 52% (after 24 h) 58% (after 48 h) |
CS MMw 190–310 kDa DD 87% |
45.27 ± 2.1 | [29] |
| Dexketoprofen- Trometamol CS-NPs |
726.8 ± 16.8 | 732 ±1.2% | 93.10 ± 7.07% (after 48 h) |
CS LMw 50–190 kDa DD * |
53.3 ± 2.2 | [25] |
| Erlotinib CS-NPs |
170.2 ± 2.9 | 74.45 ± 0.3% | 89.46% (after 24 h) |
CS LMw 40–80 kDa DD 95% |
16.2 ± 1.2 | [32] |
| Simvastatin CS-NPs | 113 ± 4.9 | 97.70 ± 0.1% | 98.60% ± 0.40% (after 14 days) |
CS LMw 50–190 kDa DD ≥ 85% |
40.80 ± 0.1 | [30] |
| Sumatriptan succinate CS-NPs | 105 ± 10.1 | 59.60 ± 2.1% | 68.03 ± 3.98% (after 72 h) |
CS LMw 40–80 kDa DD * |
21.5 ± 1.0 | [24] |
* unspecified.